New radiation technique aims to cut side effects in prostate cancer treatment

NCT ID NCT02918253

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer will receive this targeted radiation. The main goal is to see if the cancer stays under control, while also checking for improvements in urinary, bowel, and sexual function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose rate (HDR) brachytherapy (radiation)
What this could lead to: If successful, this approach could offer a way to treat early-stage prostate cancer with fewer urinary, rectal, and sexual side effects, improving quality of life.
What could go wrong: This is a small feasibility study (60 people) with no phase designation, so results are preliminary. It may not show clear benefits or could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.